`571-272-7822
`
`
`
`
`
`
`
`
`
`
` Paper No. 14
`
`Entered: November 16, 2015
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ALTAIRE PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`PARAGON BIOTECK, INC.,
`Patent Owner.
`____________
`
`Case PGR2015-00011
`Patent 8,859,623 B1
`____________
`
`
`Before SHERIDAN K. SNEDDEN, ZHENYU YANG, and
`CHRISTOPHER G. PAULRAJ, Administrative Patent Judges.
`
`YANG, Administrative Patent Judge.
`
`
`
`
`DECISION
`Institution of Post-Grant Review
`37 C.F.R. § 42.208
`
`
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`INTRODUCTION
`
`Altaire Pharmaceuticals, Inc. (“Petitioner”) filed a Petition for a post-
`
`grant review of claims 1–13 of U.S. Patent No. 8,859,623 B1 (“the ’623
`
`patent,” Ex. 1001). Paper 1 (“Pet.”). Paragon Bioteck, Inc. (“Patent
`
`Owner”) filed a Preliminary Response. Paper 7 (“Prelim. Resp.”).
`
`Thereafter, at our request (Paper 8), Petitioner filed a Reply, addressing the
`
`issue of whether the Petition properly identifies all real parties in interest
`
`(Paper 11). We have jurisdiction under 35 U.S.C. § 324, which provides
`
`that post-grant review shall not be instituted unless it is determined that “the
`
`information presented in the petition filed under section 321, if such
`
`information is not rebutted, would demonstrate that it is more likely than not
`
`that at least 1 of the challenged claims in the petition is unpatentable.”
`
`35 U.S.C. § 324(a).
`
`For the reasons provided below, we determine that Petitioner has
`
`demonstrated that it is more likely than not that at least one claim of the ’623
`
`patent is unpatentable. Because Petitioner has satisfied the threshold
`
`requirement set forth in 35 U.S.C. § 324(a), we institute a post-grant review
`
`of claims 1–13 of the ’623 patent.
`
`
`
`Related Proceedings
`
`Patent Owner identifies two district-court cases involving the parties.
`
`Paper 5, 1. Those cases, however, appear to involve issues unrelated to the
`
`’623 patent. Prelim. Resp. 6 n.7.
`
` 2
`
`
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`The ’623 Patent
`
`The ’623 patent “is directed to methods and compositions of
`
`stabilizing phenylephrine formations.” Ex. 1001, Abstract. “Phenylephrine
`
`is a selective α1-adrenergic receptor agonist used primarily as a
`
`decongestant, as an agent to dilate the pupil, and to increase blood pressure.”
`
`Id. at 1:6–8. Specifically, the ’623 patent provides “a composition
`
`comprising at least 95% R-phenylephrine hydrochloride and an aqueous
`
`buffer, wherein the composition substantially maintains an initial chiral
`
`purity of R-phenylephrine hydrochloride for at least 6 months stored
`
`between –10 to 10 degree Celsius.” Id. at 1:16–21. It also discloses
`
`“methods of dilating the pupil comprising administering a composition
`
`comprising R-phenylephrine hydrochloride topically to a mammal, wherein
`
`the composition substantially maintains the initial chiral purity of R-
`
`phenylephrine hydrochloride for at least 6 months.” Id. at 1:38–42.
`
`At the time of the ’623 patent invention, it was known that
`
`R-phenylephrine, but not S-phenylephrine, was useful to dilate the pupil. Id.
`
`at 6:21–30. Thus, “it is important that an eye drop containing Phenylephrine
`
`Hydrochloride used for dilation of the pupil contains predominantly the R-
`
`isomer in order to maintain maximum efficacy of the ophthalmic solution.”
`
`Id. at 6:30–33.
`
`According to the ’623 patent, generally, commercially available
`
`phenylephrine hydrochloride ophthalmic solutions were stored at 20 to 25
`
`degree Celsius, with the container tightly closed. Id. at 2:60–65. A solution
`
`under such condition, however, often turns brown over time and cannot be
`
` 3
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`used. Id. at 2:66–3:3. The ’623 patent states that it “provides the
`
`improvement to overcome such instability problem.” Id. at 3:4–5.
`
`
`
`Illustrative Claim
`
`Claims 1 is the sole independent claim. It reads:
`
`1.
`A method of using an ophthalmic composition for pupil
`dilation,
`the
`composition
`comprising R-phenylephrine
`hydrochloride having an initial chiral purity of at least 95% and
`an aqueous buffer, wherein the chiral purity of R-phenylephrine
`hydrochloride is at least 95% of the initial chiral purity after 6
`months, the method comprising:
`
`administering the composition into an eye of an individual in
`need thereof, wherein the composition is stored between –10 to
`10 degree Celsius prior to administration, and wherein the
`composition comprises R-phenylephrine hydrochloride having
`a chiral purity of at least 95% when administered after storage.
`
`
`
`Asserted Ground of Unpatentability
`
`Petitioner asserts the following grounds of unpatentability:
`
`1.
`
`claims 1–13 as anticipated by, or in the alternative, rendered
`
`obvious over, Altaire’s Product (“the Altaire’s Product ground”);
`
`2.
`
`claims 1–13 as anticipated by, or in the alternative, rendered
`
`obvious over, Altaire’s Package Insert,1 “or alternatively, in view of
`
`common knowledge in the art or, alternatively or in addition, in view of U.S.
`
`
`
`1 Sterile Phenylephrine Hydrochloride Ophthalmic Solution, USP
`(Revised August 2010) (Ex. 1018).
`
` 4
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`Patent No. 3,966,7492 and in further view of Syn-Tech’s Commercially
`
`Available product (“the Altaire’s Package Insert ground”);
`
`3.
`
`claims 1–13 as “obvious in view of Applicants’ Admitted Prior
`
`Art (‘AAPA’), Altaire’s Commercial Product, and/or the common
`
`knowledge in the art or, alternatively or in addition, in view of U.S. Patent
`
`No. 3,966,749” (“the AAPA ground”); and
`
`4.
`
`claims 1–13 as unpatentable “under 35 U.S.C. § 112(b) for
`
`failing to particularly point out and distinctly claim the subject matter which
`
`the joint inventors regard as the invention” (“the indefiniteness ground”).
`
`In support of its patentability challenge, Petitioner relies on the
`
`Declaration of Assad Sawaya. Ex. 1003.
`
`
`
`ANALYSIS
`
`Eligibility for Post-Grant Review
`
`The ’623 patent issued on October 14, 2014, from an application filed
`
`on November 14, 2013. Ex. 1001, (22). It does not claim the benefit of any
`
`earlier filing date. Because it issued from an application that contains a
`
`claim with an effective filing date after March 16, 2013, the ’623 patent is
`
`available for post-grant review. See Leahy-Smith America Invents Act
`
`(Pub. L. No. 112-29, 125 Stat. 284 (2011), §§ 3(n)(1), 6(f)(2)(A).
`
`The Petition was filed on May 11, 2015 (Pet. 69), within 9 months of
`
`the grant of the ’623 patent. See 35 U.S.C. § 321(c). Petitioner further
`
`
`
`2 U.S. Patent No. 3,966,749, issued on June 29, 1976 (Ex. 1011).
`
` 5
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`certifies that it has standing to seek a post-grant review of the ’623 patent.
`
`Pet. 2.
`
`
`
`Real Party in Interest
`
`Patent Owner requests that we dismiss the Petition because Petitioner
`
`should have identified Sawaya Aquebogue, LLC (“Saw Aque”) as a real
`
`party in interest. Prelim. Resp. 2. Based on the current record, we are not
`
`persuaded.
`
`A petitioner for a post-grant review must identify all real parties in
`
`interest. 35 U.S.C. § 322(a)(2); see also 37 C.F.R. § 42.8(b)(1). The real
`
`party in interest may include not only the named petitioner, but also “the
`
`party or parties at whose behest the petition has been filed.” Office Patent
`
`Trial Practice Guide (“Trial Practice Guide”), 77 Fed. Reg. 48,756, 48,759
`
`(Aug. 14, 2012). Whether a non-party is a real party in interest is a highly
`
`fact-dependent question. Id.
`
`Patent Owner argues that Saw Aque and Petitioner “are related
`
`companies under the common control, and are even run by the same
`
`individual – Assad Sawaya.” Id. at 3. According to Patent Owner,
`
`Mr. Sawaya serves as both the President of Petitioner and the General
`
`Manager of Saw Aque. Id. (citing Ex. 2001 ¶ 3). In addition, the two
`
`companies share the same address, and Petitioner’s General Counsel accepts
`
`service of legal documents for both companies at this same address. Id. at
`
`3–4 (citing Exs. 2002, 2003, 2005). Patent Owner refers to an Air State
`
`Facility permit issued by the New York State Department of Environmental
`
` 6
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`Conservation. Id. at 4 (citing Ex. 2005). Although the permit was issued to
`
`Saw Aque, the facility bore Petitioner’s name. Id. at 4 (citing Ex. 2005, 1).
`
`Patent Owner also refers to a 2011 agreement between itself and
`
`Petitioner, which allegedly involves the “manufacturing, marketing, and
`
`distribution of a selection of products and subject matter of the ’623 patent.”
`
`Id.; Ex. 2001, Ex. A. Saw Aque is not a party to the agreement. Ex. 2001
`
`¶ 21. Pursuant to that agreement, however, Patent Owner “agreed to provide
`
`certain consideration to Saw Aque.” Id., Ex. A. All the evidence, Patent
`
`Owner contends, shows that Saw Aque “has a direct interest in this
`
`proceeding and has the motivation and ability to control this proceeding.”
`
`Prelim. Resp. 6.
`
`Citing the testimony from Mr. Sawaya, Petitioner asserts that
`
`“Petitioner and Saw Aque are separate and distinct entities that have no
`
`ownership interest in one another.” Reply 4 (citing Ex. 1022 ¶ 6).3
`
`According to Mr. Sawaya, the two companies “do not have a
`
`parent/subsidiary relationship,” and are not under common control.
`
`Ex. 1022 ¶ 6. Petitioner also emphasizes that the two companies are in
`
`different fields of businesses—while Petitioner “is in the business of
`
`pharmaceutical research, development, manufacturing, supply and
`
`
`
`3 We recognize that we rely on Mr. Sawaya’s testimony regarding real party
`in interest while Patent Owner has not had an opportunity to cross-examine
`him on this issue. Upon institution, Patent Owner, should it wishes to
`pursue the issue, can cross-examine Mr. Sawaya through routine discovery.
`See 35 U.S.C. § 326(a)(5); 37 C.F.R. § 42.51.
`
` 7
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`distribution,” Saw Aque is a holding company that holds, among others, real
`
`properties. Reply 5 (citing Ex. 1022 ¶¶ 4, 8). According to Petitioner, the
`
`two companies “share the same address merely because Saw Aque owns
`
`property that it leases to Petitioner at arm’s length rates.” Id. (citing
`
`Ex. 1022 ¶ 13).
`
`Mr. Sawaya testifies that “Saw Aque does not have an ownership
`
`interest in any entity that could infringe the ’623 patent,” and “does not have
`
`the capabilities to manufacture or sell products that allegedly could be
`
`covered by the ’623 patent.” Ex. 1022 ¶ 9. As a result, Petitioner contends,
`
`Saw Aque “has no interest in challenging the claims of the ’623 patent.”
`
`Reply 5.
`
`To determine whether Saw Aque is a real party in interest to this post-
`
`grant review, we analyze whether Saw Aque “exercised or could have
`
`exercised control” over Petitioner’s participation in this proceeding. Trial
`
`Practice Guide, 77 Fed. Reg. at 48,759. In this inquiry, we are persuaded by
`
`Mr. Sawaya’s testimony that Saw Aque, a company unrelated to Petitioner
`
`and in a line of business different from Petitioner’s, “did not direct, control,
`
`or fund the preparation or filing of the Petition.” See Prelim. Resp. 8 (citing
`
`Ex. 1022 ¶ 12). Therefore, based on the current record, we determine that
`
`Petitioner has complied with the statutory requirement to identify the correct
`
`real party in interest.
`
` 8
`
`
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`Claim Construction
`
`In a post-grant review, we interpret a claim term in an unexpired
`
`patent according to its broadest reasonable construction in light of the
`
`specification of the patent in which it appears. 37 C.F.R. § 42.200(b); see
`
`also In re Cuozzo Speed Techs., LLC, 793 F.3d 1268, 1281 (Fed. Cir. 2015)
`
`(concluding that “Congress implicitly adopted the broadest reasonable
`
`interpretation standard in enacting the AIA”). Under that standard, and
`
`absent any special definitions, we assign claim terms their ordinary and
`
`customary meaning, as would be understood by one of ordinary skill in the
`
`art at the time of the invention, in the context of the entire patent disclosure.
`
`In re Translogic Tech., Inc., 504 F.3d 1249, 1257 (Fed. Cir. 2007).
`
`Petitioner proposes constructions for the following terms: (1) “chiral
`
`purity” and “initial chiral purity;” (2) “wherein the chiral purity of R-
`
`phenylephrine hydrochloride is at least 95% of the initial chiral purity after 6
`
`months;” (3) “administering the composition into an eye of an individual in
`
`need thereof, wherein the composition is stored between -10 to 10 degree
`
`Celsius prior to administration;” and (4) “allowed to be.” Pet. 31–33. Patent
`
`Owner challenges the first two constructions. Prelim. Resp. 21–22.
`
`Claim terms need only be construed to the extent necessary to resolve
`
`the controversy. Wellman, Inc. v. Eastman Chem. Co., 642 F.3d 1355, 1361
`
`(Fed. Cir. 2011). For purposes of this Decision, we determine that no terms
`
`require express construction.
`
` 9
`
`
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`The Altaire’s Product Ground
`
`Petitioner argues that claims 1–13 of the ’623 patent are unpatentable
`
`as obvious over Altaire’s Product.4 Pet. 33–45.
`
`Petitioner relies on two lots of Altaire’s products: Lot # 11578 and Lot
`
`# 11581. Pet. 34. According to Mr. Sawaya, Lot # 11578, a 2.5%
`
`phenylephrine hydrochloride ophthalmic solution, was manufactured in
`
`December 2011, and sold and distributed to an Altaire customer in October
`
`2012. Ex. 1003 ¶¶ 4, 36; Ex. 1007. Lot # 11581, a 10% phenylephrine
`
`hydrochloride ophthalmic solution, was manufactured in January 2012, and
`
`sold and distributed to another Altaire customer in October 2012. Ex. 1003
`
`¶¶ 5, 6, 36; Ex. 1009. In other words, these products were “in public use, on
`
`sale, or otherwise available to the public” before November 14, 2013, the
`
`effective filing date of the challenged claims. See 35 U.S.C. § 102(a)(1).
`
`Therefore, they qualify as prior art.
`
`Relying on the package insert, Petitioner points out that Altaire’s
`
`Product contains R-phenylephrine hydrochloride5 and an aqueous buffer, as
`
`claim 1 requires. Pet. 38 (citing Ex. 1018, 1). The package insert directs the
`
`user to place one drop of the solution in each eye for pupil dilation, also as
`
`
`
`4 Petitioner asserts two different challenges of claims 1–13 under this single
`ground: anticipation, “or, in the alternative,” obviousness. Pet. 33. We
`exercise our discretion and do not address the anticipation challenge. See
`37 C.F.R. § 42.108.
`5 Petitioner asserts that “(-) m-Hydroxy-α-[(methylamino)methyl] benzyl
`alcohol hydrochloride is the same as R-phenylephrine hydrochloride.”
`Pet. 48.
`
`
`
`10
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`claim 1 requires. Id. at 37 (citing Ex. 1018, 1), 39 (citing Ex. 1018, 2).
`
`Furthermore, the package insert instructs that the Altaire’s Product should be
`
`stored at 2–8 degree Celsius, within the temperature range recited in claim 1.
`
`Id. at 40 (citing Ex. 1018, 2).
`
`Petitioner refers to Exhibits 1012, 1016, and 1019 for teaching the
`
`chiral-purity limitations of claim 1. Id. at 35–39. According to Mr. Sawaya,
`
`Lot # 11578 in Exhibit 1012 and Lot # 11581 in Exhibit 1019 were tested
`
`after cold storage for over 13 months and over 12 months, respectively.
`
`Ex. 1003 ¶¶ 37, 38. In Exhibit 1012, the optical rotation data showed the
`
`chiral purity of Lot # 11578 was 101.5% of the R-phenylephrine
`
`hydrochloride control. Pet. 35 (citing Ex. 1012, 8). In Exhibit 1019, the
`
`HPLC data showed that no S-form of phenylephrine was detected in Lot
`
`# 11581. Id. at 37, 39; Ex. 1019. Thus, Petitioner argues, Altaire’s Product
`
`meets the limitation of claim 1, requiring “the chiral purity of R-
`
`phenylephrine hydrochloride is at least 95% of the initial chiral purity after 6
`
`months.” Pet. 39.
`
`Mr. Sawaya further states that both Lot # 11578 and Lot # 11581 in
`
`Exhibit 1016 were tested after room-temperature storage for 37 months.
`
`Ex. 1003 ¶ 24; Ex. 1016. In both cases, no S-form of phenylephrine was
`
`detected using the HPLC method. Ex. 1003 ¶ 25; Ex. 1016. Because the
`
`chiral purity of R-phenylephrine hydrochloride remained undiminished after
`
`months of storage under either cold or room temperature, Petitioner contends
`
`that the initial chiral purity would have been essentially 100%, meeting the
`
`
`
`11
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`initial-chiral-purity requirement of claim 1. Pet. 36, 39. We find
`
`Petitioner’s argument persuasive based on the evidence of record so far.
`
`Patent Owner challenges the methodology Petitioner used in
`
`determining chiral purity. Prelim. Resp. 12–18. First, according to Patent
`
`Owner, only those methods disclosed in the ’623 patent, and not the USP
`
`standard HPLC protocol used by Petitioner, can reliably detect chiral
`
`impurity. Id. at 12–15. For support, Patent Owner points us to a declaration
`
`submitted during prosecution, by Mr. Patrick H. Witham, one of the
`
`inventors of the ’623 patent, in which he states that “[n]on-chiral reverse
`
`phase column chromatographs (currently published USP HPLC method)
`
`show no or little chemical degradation of R-Phenylephrine hydrochloride in
`
`both formulations (i) and (ii).” Id. at 14 (citing Ex. 1002, 110). The
`
`significance of this statement, however, is not immediately clear to us. Read
`
`in context, the sentence appears to indicate neither storing a commercially
`
`available R-Phenylephrine hydrochloride at room temperature for six
`
`months (as in (i)), nor storing an R-Phenylephrine hydrochloride of the ’623
`
`patent at 2–8 degree Celsius (as in (ii)), led to detectable degradation.
`
`Ex. 1002, 109–10. We are not persuaded, at this stage, that Mr. Witham’s
`
`statement serves to discredit the USP standard HPLC method utilized by
`
`Petitioner as a reliable method to detect chiral impurity.
`
`Patent Owner also presents Exhibit 2014, purportedly “a study
`
`designed specifically to address whether the currently published USP
`
`method could reliably detect S-phenylephrine.” Prelim. Resp. 14. Exhibit
`
`2014 appears to be pages from a laboratory notebook with handwritten
`
`
`
`12
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`information and certain test results. At this stage of the proceeding, with
`
`only attorney argument and no other explanation from Patent Owner, we
`
`find Petitioner’s evidence sufficient for institution.
`
`Second, Patent Owner contends that the optical rotation method used
`
`by Petitioner in Exhibit 1012 provides not quantitative, but rather relative,
`
`measurements. Id. at 16–17. Patent Owner points out that Petitioner’s study
`
`relied on phenylephrine hydrochloride obtained from Sigma Aldrich as a
`
`control. Id. at 17 (citing Ex. 1012, 3). As a result, Patent Owner asserts,
`
`“[k]nowing the chiral purity of the Sigma control is critical to drawing any
`
`conclusions from the study regarding the absolute chiral purity of Lot
`
`# 11578.” Id. According to Patent Owner, the data showing a chiral purity
`
`of 101.5% for the tested R-phenylephrine hydrochloride demonstrates the
`
`impurity of the control. Id. at 18.
`
`We understand Exhibit 1012 shows data generated by Petitioner on
`
`behalf of Patent Owner, which was submitted to the FDA. See Pet. 9–11
`
`(citing Ex. 1003 ¶¶ 9–10). Petitioner asserts that the study was performed
`
`during Patent Owner’s New Drug Application, and in response to the FDA’s
`
`request for “adding a chiral purity test to the drug product specification.” Id.
`
`at 9–10. We recognize that Patent Owner has raised legitimate concerns
`
`about the purity of the Sigma control used, and how that may affect the
`
`chiral purity data relied upon by Petitioner. At this stage of the proceeding,
`
`however, there is an insufficient basis to conclude that such data are
`
`unreliable. Thus, based on the current record, even though Patent Owner’s
`
`
`
`13
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`argument here may be reasonable, we find Petitioner’s evidence sufficient to
`
`go forward with trial.
`
`Patent Owner argues that Petitioner’s witness, Mr. Sawaya, is a fact
`
`witness, and not an expert. Prelim. Resp. 18–20. We agree. Mr. Sawaya
`
`states that he makes the Declaration “based upon [his] personal knowledge
`
`of the facts stated [t]herein.” Ex. 1003 ¶ 1. In his Declaration, he does not
`
`explain his “knowledge, skill, experience, training, or education” that would
`
`provide the bases for his qualification as an expert. See Fed. R. Evid. 702.
`
`Because Mr. Sawaya is not shown to be an expert witness, we accord no
`
`weight to his opinion in that capacity.
`
`That said, the lack of expert testimony is not, as Patent Owner argues,
`
`fatal to the Petition. See Prelim. Resp. 24. Where the technology is simple,
`
`where the references are easily understandable without the need for expert
`
`explanatory testimony, or where the factual inquiries underlying the
`
`obviousness determination are not in material dispute, expert testimony,
`
`though it might be helpful, may not be indispensable. Allergan, Inc. v. Barr
`
`Labs., Inc., 501 F. App’x 965, 972 (Fed. Cir. 2013); see also Wyers v.
`
`Master Lock Co., 616 F.3d 1231, 1239 (Fed. Cir. 2010) (“[T]he legal
`
`determination of obviousness may include recourse to logic, judgment, and
`
`common sense, in lieu of expert testimony.”).
`
`Patent Owner further challenges portions of Mr. Sawaya’s
`
`Declaration, in which he testifies to the temperature and duration of the
`
`product storage. Pet. 26–27. According to Patent Owner, Mr. Sawaya fails
`
`to corroborate his statement about storing Altaire’s Product at cold
`
`
`
`14
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`temperature for over six months before testing in the studies. Id. at 19, 26–
`
`27. Patent Owner’s position is not unreasonable. But, at this stage of the
`
`proceeding, Patent Owner’s argument does not persuade us that we should
`
`decline to go forward with a trial. We emphasize that, upon institution, a
`
`post-grant review proceeding provides the opportunity for discovery of
`
`“evidence directly related to factual assertions advanced by either party in
`
`the proceeding.” See 35 U.S.C. § 326(a)(5); 37 C.F.R. § 42.51. As a result,
`
`factual challenges, like this one, would be better resolved after the parties
`
`have had an opportunity to cross-examine each other’s declarants.
`
`In sum, based on the current record, we find that Petitioner has offered
`
`sufficient evidence to show that it is more likely than not that claim 1 is
`
`unpatentable as obvious over Altaire’s Product. After considering
`
`Petitioner’s arguments and evidence with respect to the remaining claims
`
`(Pet. 42–45), we determine that Petitioner has made a sufficient showing as
`
`to those claims, as well.
`
`
`
`The Altaire’s Package Insert Ground
`
`Petitioner asserts that claims 1–13 of the ’623 patent are unpatentable
`
`under 35 U.S.C. § 102, or in the alternative, 35 U.S.C. § 103 as
`anticipated or rendered obvious in view of Altaire’s Package
`Insert, or alternatively, in view of common knowledge in the art
`or, alternatively or in addition, in view of U.S. Patent No.
`3,966,749 and in further view of Syn-Tech’s Commercially
`Available product.
`
`Pet. 45.
`
`
`
`
`
`
`
`15
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`Patent Owner argues that this ground of unpatentability “is not
`
`presented with the requisite degree of clarity or particularity and could be
`
`interpreted as including no fewer than eight separate grounds.” Prelim.
`
`Resp. 29. We agree with Patent Owner.
`
`Under the statute, a petition for a post-grant review must identify
`
`“with particularity, each claim challenged, the grounds on which the
`
`challenge to each claim is based, and the evidence that supports the grounds
`
`for the challenge to each claim.” 35 U.S.C. § 322(a)(3). In addition, a
`
`petition must include a “full statement of the reasons for the relief requested,
`
`including a detailed explanation of the significance of the evidence.”
`
`37 C.F.R. § 42.22(a)(2). The Petition fails to comply with the requirements
`
`specified in the statute and the rules. We decline to identify or analyze all
`
`possible permutations of prior art combinations that Petitioner may have
`
`sought to include in this ground. We, thus, exercise our discretion and do
`
`not institute trial on this ground. See 37 C.F.R. § 42.108.
`
`
`
`The AAPA Ground
`
`Petitioner contends that claims 1–13 of the ’623 patent are
`
`unpatentable “under 35 U.S.C. § 103 as being obvious in view of
`
`Applicants’ Admitted Prior Art (“AAPA”), Altaire’s Package Insert, and/or
`
`the common knowledge in the art or, alternatively or in addition, in view of
`
`U.S. Patent No. 3,966,749.” Pet. 57.
`
`The AAPA ground also fails to comply with the requirements
`
`specified in 35 U.S.C. §322(a)(3) and 37 C.F.R. § 42.22(a)(2). First, though
`
`
`
`16
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`presented as a single ground, with language “and/or” and “alternatively or in
`
`addition,” the AAPA ground actually represents numerous different grounds.
`
`Id. Second, Petitioner asserts this unpatentability ground based on its
`
`analysis of the originally filed claim 1, a claim different from the challenged
`
`claim 1. Id. Because the Petition does not identify with sufficient
`
`particularity either the claim challenged, or the grounds on which the
`
`challenge is based, we, again, exercise our discretion and do not institute
`
`trial on this ground.
`
`
`
`The Indefiniteness Ground
`
`Petitioner argues that claim 1 fails to particularly out and distinctly
`
`claim the subject matter of the invention. Pet. 66–68. Petitioner asserts
`
`claim 1 does not require storage at cold temperature for any minimum
`
`duration before use, even though the preamble refers to chiral purity after six
`
`months. Id. at 32–33, 66–67. According to Petitioner, however, during
`
`prosecution, both the applicants and the examiner relied on cold storage for
`
`six months to distinguish claim 1 from the prior art. Id. at 67 (citing
`
`Ex. 1002, 110–13, 167). Thus, Petitioner argues, “claim 1 is unclear as to
`
`what it encompasses,” and thus, is indefinite. Id. We are not persuaded.
`
`To satisfy the requirement under 35 U.S.C. 112(b), “claims are
`
`required to be cast in clear—as opposed to ambiguous, vague, indefinite—
`
`terms.” In re Packard, 751 F.3d 1307, 1313 (Fed. Cir. 2014). Petitioner is
`
`correct that claim 1 does not require cold storage for six months before
`
`administering the composition to a patient. Indeed, the only step of claim 1
`
`
`
`17
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`recites that the composition is “stored between –10 to 10 degree Celsius
`
`prior to administration.” Ex. 1001, 12:45–48. It does not specify how long
`
`the storage must be at that cold temperature.
`
`Patent Owner contends that claim 1 requires cold storage for six
`
`months, “such that the chiral purity after said storage is at least 95% of the
`
`initial chiral purity.” Prelim. Resp. 37. Patent Owner, however, relies on
`
`not the step of the claim, but the preamble, which explicitly recites the chiral
`
`purity “is at least 95% of the initial chiral purity after 6 months.” Ex. 1001,
`
`12:42–44 (emphasis added).
`
`This language of the preamble is also consistent with the prosecution
`
`history, which both parties emphasize. See Pet. 67 (citing Ex. 1002, 110–13,
`
`167); Prelim. Resp. 37–38 (citing Ex. 1002, 110, 113, 167). During
`
`prosecution, the applicants argued, and the examiner agreed, that claim 1
`
`was patentable because the chiral purity remained at least 95% of the initial
`
`chiral purity after cold storage for six months. Ex. 1002, 110, 113, 167.
`
`Maintaining at least 95% of the initial chiral purity after six months,
`
`however, simply describes a property of the composition to be administered.
`
`The characteristic, defined in the preamble, does not add a limitation on the
`
`duration of storage at cold temperatures recited in the “administering” step.
`
`This is especially so because the preamble requires that, after the six-month
`
`storage, the chiral purity is only at least 90.25% (i.e., “at least 95% of the
`
`initial chiral purity,” which is already “at least 95%”). See id. at 12:41–44.
`
`In contrast, the step of claim 1 requires “a chiral purity of at least 95% when
`
`administered after storage.” Id. at 12:49–50.
`
`
`
`18
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`Based on the current record, we determine that claim 1 is directed to a
`
`method of administering a composition—wherein the composition
`
`comprises R-phenylephrine hydrochloride that exhibits the property of
`
`having at least 95% of the initial chiral purity after six months—as long as
`
`the composition is stored in cold temperature before the administration.
`
`Although perhaps not articulately stated, claim 1 is cast in clear terms. See
`
`Packard, 751 F.3d at 1313. We accordingly deny Petitioner’s indefiniteness
`
`ground.
`
`
`
`CONCLUSION
`
`For the foregoing reasons, the information presented in the Petition
`
`and accompanying evidence establishes that it is more likely than not that
`
`claims 1–13 of the ’623 patent are unpatentable as obvious over Altaire’s
`
`Product.
`
`At this stage of the proceeding, the Board has not made a final
`
`determination as to the patentability of claims 1–13 or the construction of
`
`any claim term.
`
`
`
`Accordingly, it is
`
`ORDER
`
`ORDERED that pursuant to 35 U.S.C. § 324(a), a post-grant review is
`
`hereby instituted to determine whether claims 1–13 of the ’623 patent are
`
`unpatentable as obvious over Altaire’s Product;
`
`FURTHER ORDERED that no other grounds raised in the Petition are
`
`
`
`19
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`instituted;
`
`FURTHER ORDERED that pursuant to 35 U.S.C. § 324(d) and
`
`37 C.F.R. § 42.4, notice is hereby given of the institution of a trial
`
`commencing on the entry date of this decision.
`
`
`
`
`
`
`
`
`
`20
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`PETITIONER:
`
`Dipu A. Doshi
`DICKSTEIN SHAPIRO LLP
`doshid@dicksteinshapiro.com
`
`PATENT OWNER:
`
`Michael Rosato
`Steven W. Parmelee
`WILSON SONSINI GOODRICH & ROSATI
`mrosato@wsgr.com
`sparmelee@wsgr.com
`
`
`
`21
`
`
`
`
`
`